Skip to content

A prospective, multi-centralized, randomized, parallel controlled trial to compare the safety and efficacy of mechanical detachable coil in intravascular embolization of intracranial aneurysm

A prospective, multi-centralized, randomized, parallel controlled trial to compare the safety and efficacy of mechanical detachable coil in intravascular embolization of intracranial aneurysm

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046506
Enrollment
Unknown
Registered
2021-05-18
Start date
2018-03-30
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intracranial aneurysm

Interventions

Study Group/ Control Group:mechanical detachable coil developed by Shanghai Wobby Medical Technology Co., Ltd vs marketing mechanical detachable coil

Sponsors

Beijing Tiantan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. Has been diagnosed for intracranial aneurysms (small or large) by imaging diagnosis (CT, MRA or DSA) in the past 6-month; 3. Hunt-Hess Grade 0, I, II, III; 4. Patient who has been informed of the study and has signed an informed consent form where applicable according to local regulations.

Exclusion criteria

Exclusion criteria: 1. Determined by researcher that not eligible for intravascular interventional embolization treatment; 2. Liver and renal dysfunction (the ratios of ALT, AST are greater than the upper limit of normal 2 times); 3. Subject who has participated in other clinical trials in the past three months; 4. Subject who suffers from the disease which may cause treatment and evaluation difficulties (such as cancer, infection, severe metabolic diseases, mental illness, etc.), pregnancy, or presumed life expectancy of less than 1 year; 5. Woman of child-bearing potential who cannot provide a negative pregnancy test; 6. Known allergy or contraindication to aspirin, heparin, local or general anesthesia; 7. Known history of life threatening allergy to contrast dye; 8. Serum creatinine >= 2.5 mg/dL.

Design outcomes

Primary

MeasureTime frame
Occlusion rate at 6 Months post procedure;

Countries

China

Contacts

Public ContactLi Youxiang

Beijing Tiantan Hospital

liyouxiang@263.net+86 13501038666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026